|
Dr. Topper, responsible for investments within the biopharma sector, joined Frazier Healthcare in 2003 as a Venture Partner and became a General Partner in 2005. Since joining Frazier Healthcare, Dr. Topper has led several biopharma investments including CoTherix. He was responsible for the formation and financing of Arête Therapeutics, an innovative drug development company that is pursuing preclinical and clinical development of lead compounds directed at a novel proprietary target for cardiovascular and inflammatory disorders. Dr. Topper currently serves on the board of directors of Amicus Therapeutics, Arête Therapeutics, La Jolla Pharmaceuticals, Zelos Therapeutics, and is an observer on the boards of Point Biomedical and Portola Pharmaceuticals. Dr. Topper is also an advisory board member to the Harvard-Partners Center for Genetics and Genomics. Prior to joining Frazier Healthcare, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as the Vice President of Biology at COR and was responsible for managing all of its research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR, where he functioned as a clinician, instructor and basic investigator.Dr. Topper received his M.D. and Ph.D. (in Biophysics) from Stanford University School of Medicine in 1991 under the auspices of the Medical Scientist Training Program. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. | 